Phase 3, Sciatic Nerve Block With EXPAREL for Subjects Undergoing Bunionectomy
Status:
Not yet recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
The study is conducted sequentially in two parts.
Part A: The purpose is to obtain information on PK profile, pharmacodynamics (PD), efficacy,
safety, and to assess the performance of 266 mg EXPAREL vs 133 mg EXPAREL.
Part B: The purpose is to evaluate the efficacy and safety of the preferred dosage of EXPAREL
from Part A compared with bupivacaine HCl.